Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ovarimedin
- Development stage
- Unknown
- Lead developer
- NutriMed Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ovarimedin is a multi-ingredient nutraceutical developed by NutriMed Group, designed to support and normalize the functional state of the female reproductive system. The formulation is composed of standardized herbal extracts, including *Vitex agnus-castus* (chasteberry), *Cimicifuga racemosa* (black cohosh), and *Dioscorea villosa* (wild yam). These components work synergistically to modulate the hypothalamic-pituitary-ovarian axis. Specifically, *Vitex agnus-castus* acts as a dopaminergic agonist to inhibit the secretion of prolactin, while *Cimicifuga racemosa* provides selective estrogen receptor modulation. Ovarimedin is primarily indicated for women with polycystic ovary syndrome (PCOS), hyperprolactinemia, and menstrual cycle irregularities, aiming to restore hormonal balance and improve ovarian function.
- Brand names
- Ovarimedin
- Other names
- Оварімедін
02
Targets
ER (Estrogen receptor)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on Ovarimedin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ovarimedin.